Isabelle K. Vila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabelle K. Vila has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Nadine Laguette
Institut de Génétique Moléculaire de Montpellier (IGMM), université de Montpellier, CNRS UMR5535, Montpellier, France
9 shared publications - Cedric Moro
Institute of Metabolic and Cardiovascular Diseases (I2MC), Inserm, Univ Toulouse, UMR1297, Toulouse, France
7 shared publications Pierre-Marie Badin
Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, The University of Texas McGovern Medical School, Houston, Texas, USA
6 shared publications- Dominique Langin
Univ Toulouse, Inserm, Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, 31432 Toulouse, France; CHU Toulouse, Institut Fédératif de Biologie Purpan, service de biochimie, Toulouse, France; Institut Universitaire de France, IUF, Paris, France
5 shared publications - Geneviève Tavernier
Univ Toulouse III, Inst Metab & Cardiovasc Dis I2MC, Inst Natl Sante & Rech Medicale Inserm, Team MetaDiab,Paul Sabatier UPS,UMR1297, Toulouse, France
5 shared publications Katie Louche
Institut National de la Santé et de la Recherche Médicale, Inserm UMR 1048, Institute of Metabolic and Cardiovascular Diseases, and Paul Sabatier University, Toulouse, France
5 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Elsevier in Biomedical Journal
- p. 100988
Cytoplasmic DNA sensors and their regulators
- 1 May 2026
- Published by Elsevier in Biomedical Journal
- p. 100988
Open AccessCytoplasmic DNA sensors and their regulators
- Open Access
- 24 March 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (5)
DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses
Inflammatory signal termination is critical for the maintenance of homeostasis. Cyclic dinucleotides (CDNs) are second messengers that trigger inflammatory responses through the activation of the stimulator of IFN genes (STING) signaling platform. No broad-acting direct regulator of intracellular CDNs has been identified in mammals to date. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major DNA damage response actor, directly interacts with the intracellular 2′3′-cGAMP CDN through its kinase domain, tempering STING activation. DNA-PKcs also acts on the 3′3′-cGAMP bacterial CDN and pharmacological STING agonists, impacting their bioactivity and ability to mount optimal antiviral responses. STING agonism has been considered as a therapeutic avenue to alleviate immunosuppression in human pathologies. By uncovering DNA-PKcs as a CDN signaling modulator and CDNs as inhibitors of DNA-PKcs kinase activity, we provide critical insights into CDN regulation, with implications for the development of STING-targeting therapeutics.
- 24 March 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (5)
Open AccessDNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses
Inflammatory signal termination is critical for the maintenance of homeostasis. Cyclic dinucleotides (CDNs) are second messengers that trigger inflammatory responses through the activation of the stimulator of IFN genes (STING) signaling platform. No broad-acting direct regulator of intracellular CDNs has been identified in mammals to date. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major DNA damage response actor, directly interacts with the intracellular 2′3′-cGAMP CDN through its kinase domain, tempering STING activation. DNA-PKcs also acts on the 3′3′-cGAMP bacterial CDN and pharmacological STING agonists, impacting their bioactivity and ability to mount optimal antiviral responses. STING agonism has been considered as a therapeutic avenue to alleviate immunosuppression in human pathologies. By uncovering DNA-PKcs as a CDN signaling modulator and CDNs as inhibitors of DNA-PKcs kinase activity, we provide critical insights into CDN regulation, with implications for the development of STING-targeting therapeutics.
- Open Access
DNA-PK interacts with cyclic dinucleotides and inhibits type I Interferon responses
Cytosolic dsDNAs are potent immune-stimulatory molecules that trigger inflammation in several human pathologies 1,2. A major pathway for the detection of cytosolic dsDNA relies on the cyclic GMP-AMP (cGAMP) synthase (cGAS) that produces the 2’3’-cGAMP cyclic dinucleotide (CDN) for activation of the Stimulator of Interferon Genes (STING) adaptor protein that subsequently drives type I Interferon (IFN) responses 3,4. Here, we investigated the mechanism regulating intracellular 2’3’-cGAMP levels. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major player in the repair of double-strand breaks, directly regulates intracellular levels of 2’3’-cGAMP, thereby reducing STING activation. We describe that the binding of 2’3’-cGAMP to DNA-PKcs occurs in its catalytic cleft, impeding its kinase function. Contrary to other CDN regulatory mechanisms that have been shown to primarily regulate extracellular 2’3’-cGAMP, we show that DNA-PKcs also interacts with the 3’3’-cGAMP bacterial CDN, limiting its capacity to activate STING signaling. Furthermore, we found that DNA-PKcs decreases the potency of pharmacological STING activators. As STING is a major target for therapeutic interventions aiming to boost inflammatory responses in immunosuppressed contexts 5, our data bear important implications for drug development and deepens our understanding of inflammatory regulation in response to CDNs.
Open AccessDNA-PK interacts with cyclic dinucleotides and inhibits type I Interferon responses
Cytosolic dsDNAs are potent immune-stimulatory molecules that trigger inflammation in several human pathologies 1,2. A major pathway for the detection of cytosolic dsDNA relies on the cyclic GMP-AMP (cGAMP) synthase (cGAS) that produces the 2’3’-cGAMP cyclic dinucleotide (CDN) for activation of the Stimulator of Interferon Genes (STING) adaptor protein that subsequently drives type I Interferon (IFN) responses 3,4. Here, we investigated the mechanism regulating intracellular 2’3’-cGAMP levels. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major player in the repair of double-strand breaks, directly regulates intracellular levels of 2’3’-cGAMP, thereby reducing STING activation. We describe that the binding of 2’3’-cGAMP to DNA-PKcs occurs in its catalytic cleft, impeding its kinase function. Contrary to other CDN regulatory mechanisms that have been shown to primarily regulate extracellular 2’3’-cGAMP, we show that DNA-PKcs also interacts with the 3’3’-cGAMP bacterial CDN, limiting its capacity to activate STING signaling. Furthermore, we found that DNA-PKcs decreases the potency of pharmacological STING activators. As STING is a major target for therapeutic interventions aiming to boost inflammatory responses in immunosuppressed contexts 5, our data bear important implications for drug development and deepens our understanding of inflammatory regulation in response to CDNs.
- 18 April 2023
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Biologies
- Vol. 346 (G1) , 29-33
The unexpected role of the STING protein in lipid metabolism
Detection of cytosolic pathological nucleic acids is a key step for the initiation of innate immune responses. In the past decade, the stimulator of interferon genes (STING) adaptor protein has emerged as a central platform enabling the activation of inflammatory responses in the presence of cytosolic DNAs. This has prompted a plethora of approaches aiming at modulating STING activation in order to boost or inhibit inflammatory responses. However, recent work has revealed that STING is also a direct regulator of metabolic homeostasis. In particular, STING regulates lipid metabolism directly, a function that is conserved throughout evolution. This indicates that STING targeting strategies must take into consideration potential metabolic side effects that may alter disease course, but also suggests that targeting STING may open the route to novel treatments for metabolic disorders. Here we discuss recent work describing the metabolic function of STING and the implications of these findings.
- 18 April 2023
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Biologies
- Vol. 346 (G1) , 29-33
The unexpected role of the STING protein in lipid metabolism
Detection of cytosolic pathological nucleic acids is a key step for the initiation of innate immune responses. In the past decade, the stimulator of interferon genes (STING) adaptor protein has emerged as a central platform enabling the activation of inflammatory responses in the presence of cytosolic DNAs. This has prompted a plethora of approaches aiming at modulating STING activation in order to boost or inhibit inflammatory responses. However, recent work has revealed that STING is also a direct regulator of metabolic homeostasis. In particular, STING regulates lipid metabolism directly, a function that is conserved throughout evolution. This indicates that STING targeting strategies must take into consideration potential metabolic side effects that may alter disease course, but also suggests that targeting STING may open the route to novel treatments for metabolic disorders. Here we discuss recent work describing the metabolic function of STING and the implications of these findings.
- 1 September 2022
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 68, 54-68
Alternative pathways driven by STING: From innate immunity to lipid metabolism
- 1 September 2022
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 68, 54-68
Alternative pathways driven by STING: From innate immunity to lipid metabolism
- Open Access
- 14 May 2022
- Published by Elsevier in STAR Protocols
- Vol. 3 (2) , 101384
Protocol to induce and assess cGAS-STING pathway activation in vitro
- 14 May 2022
- Published by Elsevier in STAR Protocols
- Vol. 3 (2) , 101384
Open AccessProtocol to induce and assess cGAS-STING pathway activation in vitro
- Top Cited PapersOpen Access
- 4 January 2022
- Published by Elsevier in Cell Metabolism
- Vol. 34 (1) , 125-139.e8
STING orchestrates the crosstalk between polyunsaturated fatty acid metabolism and inflammatory responses
- 4 January 2022
- Published by Elsevier in Cell Metabolism
- Vol. 34 (1) , 125-139.e8
Top Cited PapersOpen AccessSTING orchestrates the crosstalk between polyunsaturated fatty acid metabolism and inflammatory responses
- Open Access
Sting orchestrates the crosstalk between polyunsaturated fatty acids metabolism and inflammatory responses
Inflammatory disorders are major health issues in which immune function and metabolic homeostasis are concertedly altered. Yet, how innate and metabolic pathways are coordinated, in homeostatic conditions, is poorly understood. Here, we demonstrate that the Stimulator of interferon genes (Sting) inhibits the Fatty acid desaturase 2 (Fads2) rate limiting enzyme in polyunsaturated Fatty acid desaturation, thereby controlling both Fatty acid (FA) metabolism and innate immunity. Indeed, we show that Sting activation increased Fads2 activity, while decreasing Fads2 levels enhanced Sting activation, establishing an anti-viral state. Remarkably, the cross-regulation between Sting and Fads2 is mediated by the cyclic GMP-AMP (cGAMP) Sting agonist and PUFAs. Indeed, PUFAs inhibit Sting activation, while cGAMP binds Fads2 and promotes its degradation. Thus, our study identifies Sting as a master regulator of the interplay between FA metabolism and inflammation. One Sentence Summary Sting inhibits polyunsaturated fatty acid metabolism.
Open AccessSting orchestrates the crosstalk between polyunsaturated fatty acids metabolism and inflammatory responses
Inflammatory disorders are major health issues in which immune function and metabolic homeostasis are concertedly altered. Yet, how innate and metabolic pathways are coordinated, in homeostatic conditions, is poorly understood. Here, we demonstrate that the Stimulator of interferon genes (Sting) inhibits the Fatty acid desaturase 2 (Fads2) rate limiting enzyme in polyunsaturated Fatty acid desaturation, thereby controlling both Fatty acid (FA) metabolism and innate immunity. Indeed, we show that Sting activation increased Fads2 activity, while decreasing Fads2 levels enhanced Sting activation, establishing an anti-viral state. Remarkably, the cross-regulation between Sting and Fads2 is mediated by the cyclic GMP-AMP (cGAMP) Sting agonist and PUFAs. Indeed, PUFAs inhibit Sting activation, while cGAMP binds Fads2 and promotes its degradation. Thus, our study identifies Sting as a master regulator of the interplay between FA metabolism and inflammation. One Sentence Summary Sting inhibits polyunsaturated fatty acid metabolism.
- 1 September 2020
- Published by Elsevier in Journal of Molecular Biology
- Vol. 432 (20) , 5529-5543
Animal Models for the Study of Nucleic Acid Immunity: Novel Tools and New Perspectives
- 1 September 2020
- Published by Elsevier in Journal of Molecular Biology
- Vol. 432 (20) , 5529-5543
Animal Models for the Study of Nucleic Acid Immunity: Novel Tools and New Perspectives
- Open Access
- 22 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (21) , eaax3333
Lysyl-tRNA synthetase produces diadenosine tetraphosphate to curb STING-dependent inflammation
The LysRS-Ap 4 A axis impairs cGAS-STING pathway activation, delaying nucleic acid-driven innate immune responses.
- 22 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (21) , eaax3333
Open AccessLysyl-tRNA synthetase produces diadenosine tetraphosphate to curb STING-dependent inflammation
The LysRS-Ap 4 A axis impairs cGAS-STING pathway activation, delaying nucleic acid-driven innate immune responses.